The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| REPCF | +9,900% | -99.94% | -77.12% | -100% |
| S&P | +14.77% | +87.2% | +13.35% | +452% |
RepliCel Life Sciences, Inc. is a regenerative medicine company, which engages in developing cell therapies for aesthetic and orthopedic conditions. Its products include RCH-01, RCS-01, RCT-01, and DermaPrecise. The company was founded by Kevin McElwee and Rolf Hoffmann on April 24, 1967 and is headquartered in Vancouver, Canada.
No news articles found for 0913693 B.c..
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | -100.0% |
| Gross Profit | $0.00K | -100.0% |
| Gross Margin | 99.85% | 0.2% |
| Market Cap | $7.40K | -99.7% |
| Net Income | -$18.22K | 88.5% |
| EBITDA | -$5.49K | 90.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.42K | -42.9% |
| Accounts Receivable | $0.00K | -100.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $43.11K | 0.0% |
| Short Term Debt | $666.45K | -27.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -8824.71% | -9388.8% |
| Return On Invested Capital | 30.91% | -12.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$19.02K | 52.2% |
| Operating Free Cash Flow | -$19.02K | 52.2% |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 9.85 | 4.06 | 2.26 | - | |
| Price to Book | -0.02 | -0.04 | -0.18 | -0.01 | -98.82% |
| Price to Sales | 8.60 | 8.75 | 3.77 | 3.79 | -63.54% |
| Price to Tangible Book Value | -0.02 | -0.04 | -0.18 | -0.01 | -98.82% |
| Enterprise Value to EBITDA | -48.90 | -31.89 | -89.43 | -232.19 | 292.21% |
| Total Debt | $430.84K | $552.41K | $701.99K | $709.57K | -23.21% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
